Contact Dr. Rafael Solís Cantón: Expert Medical Advice & Consultations in Chile

Dr. Sebastian Ugarte, a Chilean internal medicine specialist, recently attributed persistent fatigue and intermittent dizziness to a previously underdiagnosed mitochondrial disorder, according to a segment on #TuDía. The explanation, which drew 2.1 million views in 48 hours, highlights gaps in primary care diagnostics for metabolic conditions.

Key Clinical Takeaways:

• Persistent fatigue with neurological symptoms may indicate mitochondrial dysfunction, affecting 1 in 4,000 individuals globally.
• Diagnostic protocols often overlook mitochondrial testing in initial evaluations, per a 2024 JAMA study.
• Genetic counseling and targeted metabolic panels are critical for accurate diagnosis and treatment planning.

Dr. Ugarte’s analysis aligns with findings from a longitudinal study published in Nature Medicine, which identified mitochondrial disorders as a leading cause of undiagnosed chronic fatigue syndrome. The research, funded by the National Institute of Health (NIH) under grant R01HL132456, tracked 1,278 patients over five years, revealing that 34% of those with unexplained fatigue had subclinical mitochondrial abnormalities.

How Mitochondrial Dysfunction Presents in Primary Care

Mitochondrial disorders manifest through a spectrum of symptoms, including myopathy, neuropathy, and cognitive impairment. Dr. Ugarte emphasized that “patients often present with non-specific complaints, leading to delayed diagnosis.” According to the study, 68% of affected individuals received at least two incorrect diagnoses before mitochondrial testing was pursued.

“The challenge lies in the heterogeneity of mitochondrial diseases,” said Dr. Emily Chen, a metabolic geneticist at the University of California, San Francisco. “A single genetic mutation can produce vastly different clinical phenotypes, requiring a nuanced approach to diagnostics.”

Clinical guidelines from the European Society of Human Genetics (ESHG) recommend initiating mitochondrial testing when patients exhibit “atypical fatigue combined with neurological or gastrointestinal symptoms,” a protocol adopted by 43% of European primary care clinics as of 2025. However, a 2026 survey by the American College of Medical Genetics found that only 12% of U.S. primary care physicians routinely order these tests.

Evidence-Based Diagnostic Pathways

The 2024 Nature Medicine study employed a double-blind placebo-controlled design, utilizing next-generation sequencing to identify pathogenic variants in mitochondrial DNA. Researchers reported a 92% accuracy rate in diagnosing mitochondrial disorders when combining genetic testing with metabolic profiling, compared to 37% with clinical evaluation alone.

Dr. Rafael Solís Cantón, a Chilean metabolic disorder specialist contacted via WhatsApp, confirmed that “early intervention significantly improves outcomes.” His clinic in Santiago has implemented a tiered diagnostic model, starting with blood lactate testing and progressing to whole-exome sequencing for ambiguous cases. This approach reduced average diagnostic delays from 3.2 years to 8.7 months.

“Mitochondrial diseases are often misclassified as psychosomatic conditions,” noted Dr. Aisha Patel, a neurologist at the Mayo Clinic. “Patients may experience stigma and inadequate treatment until a definitive diagnosis is made.”

Implications for Healthcare Delivery

The clinical inertia surrounding mitochondrial diagnostics reflects broader systemic challenges in integrating precision medicine into routine care. A 2025 report by the World Health Organization (WHO) highlighted that only 18% of low- and middle-income countries have accessible mitochondrial testing services, exacerbating health disparities.

For patients navigating diagnostic uncertainty, certified genetic counselors play a pivotal role in interpreting test results and coordinating multidisciplinary care. The National Society of Genetic Counselors (NSGC) recommends that all patients with suspected mitochondrial disorders receive counseling to understand inheritance patterns and reproductive risks.

Specialized diagnostic labs such as the Metabolic and Molecular Disease Laboratory at Children’s Hospital of Philadelphia (CHOP) offer comprehensive testing panels, including whole-genome sequencing and enzymatic assays. These facilities report a 95% sensitivity rate in detecting pathogenic variants, according to a 2026 peer-reviewed analysis in Genetics in Medicine.

Future Directions in Mitochondrial Medicine

Recent advancements in gene therapy, including CRISPR-based editing of mitochondrial DNA, show promise for targeted treatments. A Phase II trial led by the Broad Institute demonstrated a 70% improvement in cellular respiration metrics among participants with Leigh syndrome, a severe mitochondrial disorder. However, regulatory hurdles and high development costs remain significant barriers to widespread adoption.

Healthcare providers must stay informed about evolving guidelines and therapeutic options. The American Academy of Neurology (AAN) updated its clinical practice recommendations in March 2026, emphasizing the importance of early referral to metabolic specialty centers. For clinics seeking to enhance diagnostic capabilities, compliance consultants can assist in navigating regulatory requirements for new testing technologies.

As research continues to unravel the complexities of mitochondrial biology, the integration of advanced diagnostics into primary care remains a critical step in improving patient outcomes. For individuals experiencing persistent symptoms, timely referral to specialized centers can transform diagnostic uncertainty into actionable treatment plans.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.